Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
Antonio Gonzalez-Martin
No relevant relationships to disclose
Patricia Pautier
Consultant or Advisory Role - AstraZeneca; PharmaMar; Roche
Sven Mahner
Consultant or Advisory Role - Roche
Honoraria - GlaxoSmithKline; Roche
Research Funding - Roche
Jörn Rau
No relevant relationships to disclose
Nicoletta Colombo
Consultant or Advisory Role - Roche
Honoraria - Roche
Petronella Ottevanger
No relevant relationships to disclose
Jose Maria Del Campo
No relevant relationships to disclose
Dominique Berton-Rigaud
No relevant relationships to disclose
Andreas Du Bois
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; MSD; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Johnson & Johnson; MSD; PharmaMar; Roche
Ulrich Freudensprung
Employment or Leadership Position - Roche
Ru-Amir Walker
Employment or Leadership Position - Roche
Stock Ownership - Roche
Christian Kurzeder
Honoraria - Roche
Other Remuneration - Roche